LinkedIn Profile

Access XTL Biopharmaceuticals historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:xtlb 13186929 Mar 23rd, 2024 12:00AM XTL Biopharmaceuticals Ltd. 146 3.00 Open Mar 23rd, 2024 01:04AM Mar 23rd, 2024 07:36PM XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB, TASE:XTLB.TA) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus. The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some have significant side effects. Robust clinical data on hCDR1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals. Open Open 5 HaCharoshet St. Raanana IL 4365603 XTL Biopharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:xtlb 13186929 Mar 22nd, 2024 12:00AM XTL Biopharmaceuticals Ltd. 146 3.00 Open Mar 22nd, 2024 12:37AM Mar 22nd, 2024 07:25PM XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB, TASE:XTLB.TA) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus. The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some have significant side effects. Robust clinical data on hCDR1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals. Open Open 5 HaCharoshet St. Raanana IL 4365603 XTL Biopharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:xtlb 13186929 Mar 21st, 2024 12:00AM XTL Biopharmaceuticals Ltd. 146 3.00 Open Mar 21st, 2024 06:09PM Mar 21st, 2024 06:09PM XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB, TASE:XTLB.TA) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus. The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some have significant side effects. Robust clinical data on hCDR1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals. Open Open 5 HaCharoshet St. Raanana IL 4365603 XTL Biopharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:xtlb 13186929 Mar 20th, 2024 12:00AM XTL Biopharmaceuticals Ltd. 146 3.00 Open Mar 20th, 2024 02:46AM Mar 20th, 2024 08:10PM XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB, TASE:XTLB.TA) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus. The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some have significant side effects. Robust clinical data on hCDR1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals. Open Open 5 HaCharoshet St. Raanana IL 4365603 XTL Biopharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:xtlb 13186929 Mar 19th, 2024 12:00AM XTL Biopharmaceuticals Ltd. 145 3.00 Open Mar 19th, 2024 01:55AM Mar 19th, 2024 06:42PM XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB, TASE:XTLB.TA) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus. The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some have significant side effects. Robust clinical data on hCDR1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals. Open Open 5 HaCharoshet St. Raanana IL 4365603 XTL Biopharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:xtlb 13186929 Mar 18th, 2024 12:00AM XTL Biopharmaceuticals Ltd. 145 3.00 Open Mar 18th, 2024 12:57AM Mar 18th, 2024 07:54PM XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB, TASE:XTLB.TA) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus. The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some have significant side effects. Robust clinical data on hCDR1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals. Open Open 5 HaCharoshet St. Raanana IL 4365603 XTL Biopharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:xtlb 13186929 Mar 16th, 2024 12:00AM XTL Biopharmaceuticals Ltd. 145 3.00 Open Mar 15th, 2024 11:58PM Mar 16th, 2024 07:41PM XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB, TASE:XTLB.TA) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus. The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some have significant side effects. Robust clinical data on hCDR1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals. Open Open 5 HaCharoshet St. Raanana IL 4365603 XTL Biopharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:xtlb 13186929 Mar 15th, 2024 12:00AM XTL Biopharmaceuticals Ltd. 144 3.00 Open Mar 15th, 2024 07:37AM Mar 15th, 2024 09:32AM XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB, TASE:XTLB.TA) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus. The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some have significant side effects. Robust clinical data on hCDR1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals. Open Open 5 HaCharoshet St. Raanana IL 4365603 XTL Biopharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:xtlb 13186929 Mar 14th, 2024 12:00AM XTL Biopharmaceuticals Ltd. 144 3.00 Open Mar 13th, 2024 11:57PM Mar 14th, 2024 12:54PM XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB, TASE:XTLB.TA) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus. The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some have significant side effects. Robust clinical data on hCDR1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals. Open Open 5 HaCharoshet St. Raanana IL 4365603 XTL Biopharmaceuticals Health Care Pharmaceuticals & Biotechnology
nasdaq:xtlb 13186929 Mar 13th, 2024 12:00AM XTL Biopharmaceuticals Ltd. 144 3.00 Open Mar 12th, 2024 11:51PM Mar 13th, 2024 11:24AM XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB, TASE:XTLB.TA) is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune diseases including lupus. The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of systemic lupus erythematosus (SLE). Treatments currently on the market for SLE are not effective enough for most patients and some have significant side effects. Robust clinical data on hCDR1 has been produced in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer reviewed scientific journals. Open Open 5 HaCharoshet St. Raanana IL 4365603 XTL Biopharmaceuticals Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.